SCHEMBL2118252

SCHEMBL2118252

Cc1ccc(-c2ccc(C#N)c(F)c2)cc1NS(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.54
TUBB P07437 1/20 0.54
TUBA3C P0DPH7 1/20 0.54
STAT3 P40763 1/20 0.54
TUBA1B P68363 1/20 0.54
TUBA4A P68366 1/20 0.54
TUBB4B P68371 1/20 0.54
TUBB3 Q13509 1/20 0.54
TUBB2A Q13885 1/20 0.54
TUBB8 Q3ZCM7 1/20 0.54
TUBA3E Q6PEY2 1/20 0.54
TUBA1A Q71U36 1/20 0.54
TUBA1C Q9BQE3 1/20 0.54
TUBB6 Q9BUF5 1/20 0.54
TUBB2B Q9BVA1 1/20 0.54
TUBB1 Q9H4B7 1/20 0.54
ACLY P53396 5/20 0.47
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43
EGLN2 Q96KS0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120031 0.90 ACLY (0.44) TUBB4ATUBBTUBA3CSTAT3TUBA1B
SCHEMBL2120193 0.90 ACLY (0.46) TUBB4ATUBBTUBA3CSTAT3TUBA1B
SCHEMBL2120282 0.89 TUBB4A (0.54) TUBB4ATUBBTUBA3CSTAT3TUBA1B
SCHEMBL2120606 0.89 ACLY (0.54) TUBB4ATUBBTUBA3CSTAT3TUBA1B
SCHEMBL2119785 0.83 ACLY (0.59) STAT3ACLYHSD11B1
SCHEMBL2122742 0.80 ACLY (0.42) ACLYHSD11B1ALDH1A1CYP3A4SMN1; SMN2
SCHEMBL2118236 0.79 CYP2C9 (0.54) ALDH1A1CYP3A4SMN1; SMN2TDP1
SCHEMBL2118686 0.79 PIK3CD (0.47) ACLYHSD11B1ALDH1A1CYP3A4SMN1; SMN2
SCHEMBL2120602 0.78 HSD11B1 (0.45) ACLYCYP11B1CYP11B2SLC22A12HSD11B1
SCHEMBL2121424 0.78 ALDH1A1 (0.52) ACLYSLC22A12ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 TUBB4A 1564/4885TUBB 1824/4885TUBA3C 3627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.